Study results to be presented at the 14th International
Conference on Advanced Technologies and Treatments for
Diabetes
NEW YORK, June 4, 2021 /PRNewswire/ -- DarioHealth
Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics
(DTx) market, announced today it will be presenting results of a
new study at the 14th International Conference on Advanced
Technologies and Treatments for Diabetes (ATTD 2021; June 2-5, 2021).
The study, titled "Impact of Digital Intervention Engine on
Diabetes Self-Management," examined the effect of DarioHealth's
highly personalized digital journeys on both clinical and
engagement outcomes, applying user-specific digital intervention
flows for behavioral change to increase user digital
engagement.
This new research is a retrospective study of 246 DarioHealth
users, and presents several meaningful outcomes achieved by the
users:
- The percentage of users who measured blood glucose was
significantly higher in the test group of 127 Dario users receiving
interventions driven by the digital intervention engine: 14% in
first 30 days and 22% in 30-60 days;
- The average number of blood glucose measurements increased by
6% and 17% at first 30 days and 30-60 days, respectively; and
- Recency (average number of days between blood glucose
measurements) was significantly improved by 30% in the test
group.
Most digital health solutions are personalized by applying
generalized predictions across groups of "like" participants, not
adapting to the truly unique needs of each participants. Dario's
study found that personalizing the clinical interventions in
response to unique individual circumstances, made possible by a
powerful combination of AI, dynamically personalized user journeys,
coaching, and behavior science, helps to durably improve
self-monitoring and platform engagement among inconsistent
users.
"The potential benefit of this research could be life-changing
for so many people," said Dr. Yifat Hershcovitz, Ph.D., Scientific
and Clinical Director at DarioHealth and one of the authors of the
study. "In the context of busy day-to-day life, simply remembering
to perform blood glucose measurements at meaningful intervals may
be a challenge. The results of this study confirm that
DarioHealth's platform and hyper-personalized approach makes it
much easier for people to remember to incorporate measuring glucose
levels into their everyday lives, improving and maintaining health
outcomes."
"We believe that diabetes self-management is ripe for
innovation, and our research illustrates the important role a
digital intervention engine can play in helping people stay engaged
in their diabetes management," said Dr. Omar Manejwala, Chief Medical Officer of
DarioHealth. "DarioHealth is proud of our work to deliver a
sustainable and impactful digital therapeutic solution, and these
latest findings only add to our strong body of evidence that our
hyper-personalized approach produces real, measurable
improvements."
DarioHealth is presenting additional research at ATTD, titled
"Impact of a Digital Therapeutic on Insulin Self-Management." For
registration inquiries and additional information on ATTD 2021,
visit ATTD.kenes.com. Attendance is welcomed and encouraged to all.
Registration is discounted due to the conference being held
virtually this year.
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital
therapeutics company revolutionizing how people with chronic
conditions manage their health. Dario's next-generation,
AI-powered, digital therapeutic solutions support more than just an
individual's disease. Dario provides adaptive, personalized
experiences that drive behavior change through evidence-based
interventions, intuitive, clinically proven digital tools,
high-quality software, and coaching to help individuals improve
health and sustain meaningful outcomes. Dario offers one of the
highest-rated diabetes and hypertension solutions on the market.
The company's cross-functional team operates at the intersection of
life sciences, behavioral science, and software technology and is
rapidly expanding into new chronic conditions and geographic
markets, using a performance-based approach to improve its users'
health. Dario makes the right thing to do the easy thing to do. To
learn more about DarioHealth and its digital health solutions, or
for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. related thereto contain or may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements that
are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the generality of the
foregoing, words such as "plan," "project," "potential," "seek,"
"may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, the Company is using
forward-looking statements in this press release when it discusses
the study findings, that the potential benefit of the study results
could be life-changing for so many people, that diabetes
self-management is ripe for innovation and that the findings add to
its strong body of evidence that our hyper-personalized approach
produces real, measurable improvements. Readers are cautioned that
certain important factors may affect the Company's actual results
and could cause such results to differ materially from any
forward-looking statements that may be made in this news release.
Factors that may affect the Company's results include, but are not
limited to, regulatory approvals, product demand, market
acceptance, impact of competitive products and prices, product
development, commercialization or technological difficulties, the
success or failure of negotiations and trade, legal, social, and
economic risks, and the risks associated with the adequacy of
existing cash resources. Additional factors that could cause or
contribute to differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™) may differ
significantly from those set forth in the forward-looking
statements. The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
DarioHealth Corporate Contact:
Suzanne Bedell
VP Marketing
suzanne@dariohealth.com
+1-347-767-4220
Media Contact:
Josephine Galatioto
Josephine.Galatioto@russopartnersllc.com
+1-212-845-4262
View original
content:http://www.prnewswire.com/news-releases/dariohealth-releases-study-demonstrating-the-impact-of-personalized-digital-interventions-to-improve-self-management-of-diabetes-301305650.html
SOURCE DarioHealth Corp.